The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety analysis of the randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
 
Takanori Watanabe
No Relationships to Disclose
 
Akihito Tsuji
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Manabu Shiozawa
No Relationships to Disclose
 
Hirofumi Ota
No Relationships to Disclose
 
Hironaga Satake
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Taichi Yabuno
No Relationships to Disclose
 
Junichi Hasegawa
No Relationships to Disclose
 
Mitsugu Kochi
No Relationships to Disclose
 
Dai Manaka
No Relationships to Disclose
 
Tamotsu Sagawa
No Relationships to Disclose
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yutaro Kubota
No Relationships to Disclose
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Nippon Kayaku; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Takeda
Research Funding - Chugai Pharma; Daiichi Sankyo (Inst); Lilly Japan (Inst); Sanofi; Taiho Pharmaceutical; Takeda (Inst)
 
Takashi Sekikawa
No Relationships to Disclose
 
Masato Nakamura
Honoraria - Bayer; Chugai Pharma; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Masahiro Takeuchi
Consulting or Advisory Role - Hisamitsu Pharmaceutical; kyorindai; Taiho Pharmaceutical
 
Wataru Ichikawa
Honoraria - Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo; Merck Serono (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masashi Fujii
Travel, Accommodations, Expenses - Japan Clinical Cancer Research Organization; Taiho Pharmaceutical